Gürü Meltem
Department of Psychiatry, Etlik City Hospital, University of Health Sciences, Ankara, Turkey.
Med Sci Monit. 2025 Jun 25;31:e948984. doi: 10.12659/MSM.948984.
BACKGROUND Methylphenidate (MPH) is widely prescribed for attention deficit hyperactivity disorder (ADHD), but non-medical use is increasing, particularly in academic settings, for cognitive enhancement. This study aims to distinguish individuals using MPH for ADHD treatment from those misusing it by analyzing clinical and behavioral characteristics. MATERIAL AND METHODS This retrospective study was conducted at a university-affiliated psychiatric outpatient clinic in Türkiye. Data were collected from structured psychiatric evaluations by a single psychiatrist between January and December 2024. A total of 135 individuals who requested MPH were included. Misuse was defined as use without an ADHD diagnosis, exceeding the prescribed dose, or use through non-oral routes. Participants were categorized into 4 groups based on diagnosis and misuse patterns. Data on demographics, psychiatric history, MPH use, and follow-up attendance were analyzed using descriptive and comparative methods. RESULTS Of the 135 participants, 3% were ADHD-diagnosed misusers, 33.3% were ADHD-diagnosed non-misusers, 11.9% were non-ADHD misusers, and 51.8% were non-ADHD non-misusers. Non-ADHD misusers were older (mean age 25 vs 22 years, P<0.001), had later MPH initiation (23 vs 15 years, P<0.001), more often held a PhD (Doctor of Philosophy) or an equivalent higher degree (23.3% vs 2.0%, P<0.001), had lower follow-up attendance (32.6% vs 93.9%, P<0.001), and preferred short-acting MPH (73.3% vs 20.4%, P<0.001). ADHD-diagnosed individuals were more likely to have a family psychiatric history (69.4% vs 21.0%, P<0.001). CONCLUSIONS Misuse patterns differ significantly from medically indicated use. Strengthening diagnostic accuracy and implementing effective monitoring protocols in academic settings are essential for preventing misuse and supporting ADHD treatment.
哌甲酯(MPH)被广泛用于治疗注意力缺陷多动障碍(ADHD),但非医疗用途正在增加,尤其是在学术环境中用于认知增强。本研究旨在通过分析临床和行为特征,区分使用MPH治疗ADHD的个体与滥用MPH的个体。
本回顾性研究在土耳其一家大学附属精神科门诊进行。数据收集自2024年1月至12月期间由一名精神科医生进行的结构化精神评估。共有135名申请使用MPH的个体被纳入研究。滥用被定义为未被诊断为ADHD而使用、超过规定剂量或通过非口服途径使用。参与者根据诊断和滥用模式分为4组。使用描述性和比较性方法分析人口统计学、精神病史、MPH使用情况和随访出勤率等数据。
135名参与者中,3%为被诊断为ADHD的滥用者,33.3%为被诊断为ADHD的非滥用者,11.9%为未被诊断为ADHD的滥用者,51.8%为未被诊断为ADHD的非滥用者。未被诊断为ADHD的滥用者年龄较大(平均年龄25岁对22岁,P<0.001),开始使用MPH的时间较晚(23岁对15岁,P<0.001),拥有博士学位或同等更高学位的比例更高(23.3%对2.0%,P<0.001),随访出勤率较低(32.6%对93.9%,P<0.001),且更喜欢使用短效MPH(73.3%对20.4%,P<0.001)。被诊断为ADHD的个体更有可能有家族精神病史(69.4%对21.0%,P<0.001)。
滥用模式与医学指示性使用有显著差异。在学术环境中加强诊断准确性并实施有效的监测方案对于防止滥用和支持ADHD治疗至关重要。